Providing due diligence for a company developing R&D tools using pluripotent stem cells

Challenge: A UK-based VC wished to invest in a biotech spin-out focussed on the development of R&D tools using induced pluripotent stem cells (iPSCs) as organoids to mimic human tissues. These...
Learn More

Investor due diligence on preclinical stage vaccine platform technology

Challenge: Following a pre-due diligence exercise, an investment firm asked Alacrita to conduct a deeper due diligence on a biotech company's vaccine platform technology targeted towards infectious...
Learn More

Investor due diligence on clinical stage oncology therapeutic company

Challenge: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority...
Learn More

Due diligence for VC firm

Challenge: A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target. Alacrita...
Learn More

Providing reality checks on commercial opportunities

Challenge: A transatlantic life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality...
Learn More

Providing diagnostics due diligence

Challenge: A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.
Learn More

Preclinical due diligence of novel live biotherapeutic

Challenge: An early-stage venture fund asked Alacrita to review the opportunity for reinvestment in a biotech developing a novel live biotherapeutic for the treatment of inflammatory bowel disorders...
Learn More

Due diligence for a new imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Providing an oncology cell therapy reality check

Challenge: A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment with a very short deadline.
Learn More

Providing biotech due diligence of a Phase lll oncology program

Challenge: A major pharmaceutical company asked us for support in the due diligence and assessment of a Phase III in-licensing opportunity. The drug in question had met its primary endpoint in a...
Learn More

Providing in-licensing due diligence on a Phase IIb respiratory drug

Challenge: A pharma company needed help conducting due diligence on an in-licensing/acquisition candidate for a Phase IIb respiratory drug.
Learn More

Vendor due diligence of a regulatory dossier

Challenge: A biotech company with a novel oral drug delivery technology platform was looking to out-license its lead asset, a reformulated generic therapeutic in a new, non-opioid pain, indication,...
Learn More